For Fevicol maker Pidilite, its rich valuation could prove to be a sore spot
In the June quarter, or the first quarter of financial year 2024-25, Pidilite impressed investors with an underlying volume growth (UVG) of 9.6% year-on-year. While this is lower than the double-digit UVG of 15.2% seen in the preceding March quarter, it is still nothing to sneeze at. Volumes in the consumer and bazaar and business-to-business…